MARKET

QURE

QURE

Uniqure
NASDAQ
20.28
+0.75
+3.84%
After Hours: 20.28 0 0.00% 16:31 10/04 EDT
OPEN
19.64
PREV CLOSE
19.53
HIGH
20.34
LOW
19.64
VOLUME
562.99K
TURNOVER
0
52 WEEK HIGH
36.55
52 WEEK LOW
12.52
MARKET CAP
947.67M
P/E (TTM)
-8.2583
1D
5D
1M
3M
1Y
5Y
uniQure to Participate in Upcoming Industry Conferences in October
LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upco...
GlobeNewswire · 1d ago
OMER, GLBE and QURE are among after hour movers
Gainers: Global-E Online  (GLBE) +4%. NETGEAR (<a href="https://seekingal...
Seekingalpha · 09/26 21:10
uniQure to Participate in Upcoming Industry Conferences in September
LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upc...
GlobeNewswire · 09/06 11:05
These Analysts Just Made A Neat Downgrade To Their uniQure N.V. (NASDAQ:QURE) EPS Forecasts
The latest analyst coverage could presage a bad day for uniQure N.V. ( NASDAQ:QURE ), with the analysts making...
Simply Wall St. · 08/14 12:23
Roblox's Stock Gets A Price Target Cut By This Analyst; Also Check Out Some Other Major PT Changes
Truist Securities boosted the price target on Roblox Corporation (NYSE: RBLX) from $29 to $45. However, Truist Securities analyst Matthew Thornton maintained the stock with a Hold. Roblox shares fell 1.3% to $48.29 in pre-market trading.
Benzinga · 08/09 12:22
--Wells Fargo Securities Cuts uniQure N.V's Price Target to $24 From $34, Keeps Equalweight Rating
--Wells Fargo Securities Cuts uniQure N.V's Price Target to $24 From $34, Keeps Equalweight Rating
MT Newswires · 08/09 11:49
--Chardan Research Adjusts uniQure's Price Target to $60 From $65, Reiterates Buy Rating
--Chardan Research Adjusts uniQure's Price Target to $60 From $65, Reiterates Buy Rating
MT Newswires · 08/09 05:31
Nasdaq Turns Lower; Crude Oil Rises Over 1%
U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday.
Benzinga · 08/08 18:38
More
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers kinds of Uniqure NV stock information, including NASDAQ:QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.